A Phase 1 interventional study of (+)-Epicatechin in Pre-diabetes, sponsored by Veterans Medical Research Foundation. Completed at 1 site in United States. Open to participants aged 21 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-17.
Sponsored by Veterans Medical Research Foundation · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 350 studies in Glucose Intolerance with a site in United States — 43 open to participants now, 65 under way, none of them phase 3. Glucose Intolerance · United States.
Among the 350 studies in Glucose Intolerance with a site in United States, this one is the 271st largest by enrollment of the 307 interventional ones that give a count, is one of 15 that started in 2014, is one of 16 in phase 1, and was the 145th registered.
793 studies on the registry are indexed under Glucose Intolerance; 113 are open to participants now.
Browse Glucose Intolerance studies →43 of the 350 studies in Glucose Intolerance with a site in United States are open now. Recruiting first, the newest first:
Arizona State University · Sites in United States
Ages 18–65
Applied Science & Performance Institute · Sites in United States
Ages 50–75 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 18–75
Pennington Biomedical Research Center · Sites in United States
Ages 25–50 · Healthy volunteers
Albert Einstein College of Medicine · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 68 Glucose Intolerance studies recruiting now, 13 (19%) set no upper age limit and 50 (74%) stop at 75 or younger; 9 take children under 18; 32 take healthy volunteers.
This study: 21 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
350 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 36 · Phase 3 15 · Phase 4 28
First in 1994; this study’s year is marked. 15 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 56 across 660 interventional studies indexed under Glucose Intolerance.
Median enrollment 50 across the 307 interventional studies, 107 across the 40 observational. Of the 261 that completed or were terminated, 100 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 350 have an industry lead sponsor. The 10 most frequent:
Veterans Medical Research Foundation is the lead sponsor of 43 studies on the registry; 9 are open to participants now.
Veterans Medical Research Foundation has 2 studies filed under Glucose Intolerance — fewer than ten, so there is no comparison to draw.
25 of the studies in Glucose Intolerance with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
| NCT06921902Abbott Diabetes CareGlycemic Metrics and Patterns in People With and Without Prediabetes | 2026-12 |
| NCT05465616ViomeEfficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c | 2026-12-13 |
| NCT05041491University of Colorado, DenverBreaking up Sedentary Time to Improve Glucose Control in a Population at Risk for Developing Type 2 Diabetes | 2026-12-15 |
| NCT06607341Johns Hopkins UniversityCommunity Engagement Alliance Against Disparities | 2026-12-20 |
Add all 25 to your calendar (.ics) → With an account.
Among the 350 studies in Glucose Intolerance with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Early Phase Pre-Clinical and Initial Clinical Research on (+)- Epicatechin.
This project is a double-blinded randomized Phase I study that will include dose-ranging one day PK and pharmacodynamic (PD) studies. Subjects will include healthy individuals and subjects who meet the American Diabetes Association (ADA) criteria for pre-diabetes, including IFG.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4 subjects randomized to one dose of 10 mg (+)-epicatechin taken orally
Drug: (+)-Epicatechin
4 subjects randomized to one dose of 30 mg (+)-epicatechin taken orally
Drug: (+)-Epicatechin
4 subjects randomized to one dose of 100 mg (+)-epicatechin taken orally
Drug: (+)-Epicatechin
Drug page: (+)-epicatechinStudies of (+)-epicatechin(+)-epicatechin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.
Also known as: Epicatechin
Change From Baseline in Circulating Urinary Concentrations of Intact Epicatechin and Epi Metabolites
This will be initial PK study on synthetic (+)-epicatechin in humans. Circulating and urinary concentrations of intact epicatechin and epicatechin metabolites, including specific enantiomers
Time frame: Baseline and 24 hours
Change From Baseline in Major Safety Endpoints
Clinically significant differences in the major safety endpoints are defined as: BP (10 mm Hg change), HR (10 bpm), creatinine (\>1.5 ULN), and highly conservative changes in alkaline phosphatase and liver transaminases (\>1.5 ULN).
Time frame: Baseline and 24 hours
Change From Baseline in Circulating Glucose Concentrations (mg/dL*24hr)
Time frame: Baseline and 24 hours
Change From Baseline in Circulating Insulin Concentrations (uU/mL*24hr)
Time frame: Baseline and 24 hours
Change From Baseline in Circulating C-Peptide Concentrations (ng/mL*24hr)
Time frame: Baseline and 24 hours
| Milestone | 10 mg (+)-Epicatechin | 30 mg (+)-Epicatechin | 100 mg (+)-Epicatechin |
|---|---|---|---|
| Started | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 |
This will be initial PK study on synthetic (+)-epicatechin in humans. Circulating and urinary concentrations of intact epicatechin and epicatechin metabolites, including specific enantiomers
| nM*hr | 10 mg (+)-Epicatechin | 30 mg (+)-Epicatechin | 100 mg (+)-Epicatechin |
|---|---|---|---|
| Metabolites (AUC nM*hr) | 105.8 ± 122.2 | 132.7 ± 148.0 | 162.3 ± 209.8 |
| epicatechin-sulfate (AUC nM*hr) | 291.3 ± 119.2 | 1639 ± 389.0 | 3031 ± 1543 |
| epicatechin-glucuronide (AUC nM*hr) | 3.375 ± 2.488 | 47.18 ± 39.41 | 398.3 ± 292.7 |
| Methyl-epi-sulfate (AUC nM*hr) | 457.8 ± 211.5 | 3190 ± 496.6 | 16699 ± 7218 |
| Total parent compound and metabolites (AUC nM*hr) | 840.3 ± 311.1 | 4996 ± 570.0 | 22563 ± 10335 |
Clinically significant differences in the major safety endpoints are defined as: BP (10 mm Hg change), HR (10 bpm), creatinine (\>1.5 ULN), and highly conservative changes in alkaline phosphatase and liver transaminases (\>1.5 ULN).
| participants | 10 mg (+)-Epicatechin | 30 mg (+)-Epicatechin | 100 mg (+)-Epicatechin |
|---|---|---|---|
| Change From Baseline in Major Safety Endpoints | 0 | 0 | 0 |
| mg/dL*24hr | 10 mg (+)-Epicatechin | 30 mg (+)-Epicatechin | 100 mg (+)-Epicatechin |
|---|---|---|---|
| Change From Baseline in Circulating Glucose Concentrations (mg/dL*24hr) | 368.3 ± 158.5 | 342.6 ± 193.5 | 513.4 ± 185.6 |
| uU/mL*24 hr | 10 mg (+)-Epicatechin | 30 mg (+)-Epicatechin | 100 mg (+)-Epicatechin |
|---|---|---|---|
| Change From Baseline in Circulating Insulin Concentrations (uU/mL*24hr) | 1192 ± 488.5 | 707.2 ± 211.5 | 1334 ± 666.5 |
| ng/mL*24hr | 10 mg (+)-Epicatechin | 30 mg (+)-Epicatechin | 100 mg (+)-Epicatechin |
|---|---|---|---|
| Change From Baseline in Circulating C-Peptide Concentrations (ng/mL*24hr) | 61.74 ± 27.64 | 57.56 ± 28.56 | 64.23 ± 27.11 |
Collected over 9 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 10 mg (+)-Epicatechin | — | 0/4 (0%) | 0/4 (0%) |
| 30 mg (+)-Epicatechin | — | 0/4 (0%) | 0/4 (0%) |
| 100 mg (+)-Epicatechin | — | 0/4 (0%) | 1/4 (25%) |
| Event | 10 mg (+)-Epicatechin | 30 mg (+)-Epicatechin | 100 mg (+)-Epicatechin |
|---|---|---|---|
| Intermittent HeadachesNervous system disorders | 0/4 | 0/4 | 1/4 |
| Age, Categorical(Participants) | 10 mg (+)-Epicatechin | 30 mg (+)-Epicatechin | 100 mg (+)-Epicatechin | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 3 | 4 | 0 | 7 |
| >=65 years | 1 | 0 | 4 | 5 |
| Sex: Female, Male(Participants) | 10 mg (+)-Epicatechin | 30 mg (+)-Epicatechin | 100 mg (+)-Epicatechin | Total |
|---|---|---|---|---|
| Female | 1 | 2 | 1 | 4 |
| Male | 3 | 2 | 3 | 8 |
| Race (NIH/OMB)(Participants) | 10 mg (+)-Epicatechin | 30 mg (+)-Epicatechin | 100 mg (+)-Epicatechin | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 0 | 0 | 3 |
| White | 0 | 4 | 4 | 8 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | 10 mg (+)-Epicatechin | 30 mg (+)-Epicatechin | 100 mg (+)-Epicatechin | Total |
|---|---|---|---|---|
| United States | 4 | 4 | 4 | 12 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Sep 2014, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: (+)-epicatechin
Veterans Medical Research Foundation